Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Table 1

Basic characteristics of the clinical trials in the analysis.

Study	Publication year	Design	Registered number	No. of patients	No. of males	Mean age (range, year)	Brain metastasis	Immunotherapy	Chemotherapy
M. Reck	2013	A randomized, double-blind, multicenter phase 2 trial	NCT00527735	130	98	57–59	NR	Ipilimumab	Paclitaxel and carboplatin
M. Reck	2016	A randomized, double-blind, multicenter phase 3 trial	NCT01450761	1132	758	62–63	NR	Ipilimumab	Etoposide and platinum
L. Horn	2018	A randomized, double-blind, multicenter, phase 1 (safety) and phase 3 (efficacy) trial	NCT02763579	403	261	64	35	Atezolizumab	Etoposide and carboplatin
L. Paz-Ares	2019	A randomized, open-label, multicenter phase 3 trial	NCT03043872	537	374	62–63	55	Durvalumab	Etoposide and platinum

NR not reported.